Form 4: Bio-Rad Laboratories Executive Acquires Stock Options
SEC Form 4 Filing
Eva Anette Engelhardt, EVP and President of CDG at Bio-Rad Laboratories, acquired stock options on March 3, 2025.
Summary
- Eva Anette Engelhardt, an executive at Bio-Rad Laboratories, filed a Form 4 with the SEC.
- The filing reports a transaction involving non-derivative and derivative securities.
- Specifically, Engelhardt acquired 2,918 non-qualified stock options at an exercise price of $256.45 on March 3, 2025.
- These options vest over four years, at a rate of 25% per year, starting on the grant's anniversary date.
- The options expire on March 3, 2035.
- Following the transaction, Engelhardt directly owns 2,918 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future performance.
Stakeholder Impact
- The transaction provides insight into executive compensation and alignment of interests with shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of earliest transaction: stock options acquired. |
| 03/03/2025 | Stock options granted at $256.45. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
| 03/03/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.